Cytovia Therapeutics Presents New Preclinical Data for Its GPC3 Flex-NK™ Cell Engager Antibody in Combination

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it is presenting new preclinical data for its GPC3 Flex-NK™ cell engager antibody in combination with natural killer cells at the European Society of Medical Oncology’s annual congress in Paris, France on September 12th, 2022.

The poster is available on both Cytovia and ESMO’s websites and will be displayed from 9AM-5PM CET and presented from 12PM-1PM CET on Monday, September 12^th, 2022 (Poster Session 13, Hall 4, Abstract 756P).

Also Read: Artemis Health and Zerigo Health Announce Partnership to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditions

Background: GPC3 is an oncofetal antigen that is highly expressed in HCC while it is hardly expressed in adult normal tissues except placenta. CYT-303 is a multifunctional bispecific NK cell engager built on our Flex-NKTM scaffold, which engages NK cells through NKp46 and targets GPC3 expressed on tumor cells.

Conclusions:

• CYT-303 showed dose-dependent HCC tumor growth inhibition in PBNK and iNK cell injected HCC tumor models.
• Dose-dependent increases in CYT-303 concentrations in tumor and blood were observed in the PBNK injected HCC tumor model showing the potential for CYT-303 to penetrate solid tumors.
• CYT-303 treated animals showed significant decreases in blood PBNKs suggesting CYT-303 may facilitate trafficking of these cells from blood to the tumor.
• Bell shaped dose-response observed with CYT-303 monotherapy in the PBNK injected HCC tumor model is consistent with CYT-303 in vitro studies showing similar dose-responses for PBNK and HCC tumor binding and tumor cytolysis.
• The linear dose-response observed with CYT-303 combination therapy with iNK cells in the HCC tumor model is consistent with the in vitro linear dose-response observed with iNK combination for cytolysis of HCC tumors.
• CYT-303 treatment resulted in reductions in blood AFP levels in both the PBNK and iNK injected HCC tumor models showing the utility of this biomarker for CYT-303 clinical studies.
• These CYT-303 preclinical proof-of-concept studies support clinical development of CYT-303 in HCC.